|
1
|
Wolf S, Barton D, Kottschade L, Grothey A
and Loprinzi C: Chemotherapy-induced peripheral neuropathy:
Prevention and treatment strategies. Eur J Cancer. 44:1507–1515.
2008.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Gaballah A, Shafik A, Elhusseiny K and
Ashraf M: Chemotherapy-induced peripheral neuropathy in Egyptian
patients: Single institution retrospective analysis. Asian Pac J
Cancer Prev. 19:2223–2227. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Miltenburg NC and Boogerd W:
Chemotherapy-induced neuropathy: A comprehensive survey. Cancer
Treat Rev. 40:872–882. 2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Pignata S, De Placido S, Biamonte R,
Scambia G, Di Vagno G, Colucci G, Febbraro A, Marinaccio M,
Lombardi AV, Manzione L, et al: Residual neurotoxicity in ovarian
cancer patients in clinical remission after first-line chemotherapy
with carboplatin and paclitaxel: The Multicenter Italian Trial in
Ovarian cancer (MITO-4) retrospective study. BMC Cancer.
6(5)2006.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Park SB, Kwok JB, Asher R, Lee CK, Beale
P, Selle F and Friedlander M: Clinical and genetic predictors of
paclitaxel neurotoxicity based on patient-versus clinician-reported
incidence and severity of neurotoxicity in the ICON7 trial. Ann
Oncol. 28:2733–2740. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
National Cancer Institute Division of
Cancer Treatment and Diagnosis: Common Terminology Criteria for
Adverse Events (CTCAE) v4.0. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40.
Accessed July 15, 2016.
|
|
7
|
Griffith KA, Couture DJ, Zhu S, Pandya N,
Johantgen ME, Cavaletti G, Davenport JM, Tanguay LJ, Choflet A,
Milliron T, et al: Evaluation of chemotherapy-induced peripheral
neuropathy using current perception threshold and clinical
evaluations. Support Care Cancer. 22:1161–1169. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Wolf SL, Barton DL, Qin R, Wos EJ, Sloan
JA, Liu H, Aaronson NK, Satele DV, Mattar BI, Green NB and Loprinzi
CL: The relationship between numbness, tingling, and
shooting/burning pain in patients with chemotherapy-induced
peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20
instrument, N06CA. Support Care Cancer. 20:625–632. 2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Haryani H, Fetzer SJ, Wu CL and Hsu YY:
Chemotherapy-induced peripheral neuropathy assessment tools: A
systematic review. Oncol Nurs Forum. 44:E111–E123. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Doi D, Ota Y, Konishi H, Yoneyama K and
Araki T: Evaluation of the neurotoxicity of paclitaxel and
carboplatin by current perception threshold in ovarian cancer
patients. J Nippon Med Sch. 70:129–134. 2003.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Matsuoka A, Mitsuma A, Maeda O, Kajiyama
H, Kiyoi H, Kodera Y, Nagino M, Goto H and Ando Y: Quantitative
assessment of chemotherapy-induced peripheral neurotoxicity using a
point-of-care nerve conduction device. Cancer Sci. 107:1453–1457.
2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Sato J, Mori M, Nihei S, Takeuchi S,
Kashiwaba M and Kudo K: Objective evaluation of
chemotherapy-induced peripheral neuropathy using quantitative pain
measurement system (Pain Vision®), a pilot study. J
Pharm Health Care Sci. 3(21)2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Gewandter JS, Chaudari J, Ibegbu C, Kitt
R, Serventi J, Burke J, Culakova E, Kolb N, Sluka KA, Tejani MA and
Mohile NA: Wireless transcutaneous electrical nerve stimulation
device for chemotherapy-induced peripheral neuropathy: An
open-label feasibility study. Support Care Cancer. 27:1765–1774.
2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Inui K and Kakigi R: Pain perception in
humans: Use of intraepidermal electrical stimulation. J Neurol
Neurosurg Psychiatry. 83:551–556. 2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kukidome D, Nishikawa T, Sato M, Igata M,
Kawashima J, Shimoda S, Matsui K, Obayashi K, Ando Y and Araki E:
Measurement of small fibre pain threshold values for the early
detection of diabetic polyneuropathy. Diabet Med. 33:62–69.
2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Suzuki C, Kon T, Funamizu Y, Ueno T, Haga
R, Nishijima H, Arai A, Tomiyama M and Baba M: Elevated pain
threshold in patients with asymptomatic diabetic neuropathy: An
intraepidermal electrical stimulation study. Muscle Nerve.
54:146–149. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Vasey PA, Jayson GC, Gordon A, Gabra H,
Coleman R, Atkinson R, Parkin D, Paul J, Hay A and Kaye SB:
Scottish Gynaecological Cancer Trials Group. Phase III randomized
trial of docetaxel-carboplatin versus paclitaxel-carboplatin as
first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst.
96:1682–1691. 2004.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ewertz M, Qvortrup C and Eckhoff L:
Chemotherapy-induced peripheral neuropathy in patients treated with
taxanes and platinum derivatives. Acta Oncol. 54:587–591.
2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Eckhoff L, Knoop A, Jensen MB and Ewertz
M: Persistence of docetaxel-induced neuropathy and impact of
quality of life among breast cancer survivors. Eur J Cancer.
51:292–300. 2015.PubMed/NCBI View Article : Google Scholar
|
